Aptevo Therapeutics Inc Quick Ratio (APVO) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Aptevo Therapeutics Inc   (NASDAQ: APVO)

Aptevo Therapeutics Inc 's Quick Ratio

APVO's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Aptevo Therapeutics Inc 's Cash & cash equivalent grew by 23.9 % in the Q2 2026 sequentially, faster than Current Liabilities, this led to improvement in Aptevo Therapeutics Inc 's Quick Ratio to 3.47, above Aptevo Therapeutics Inc average Quick Ratio.

Within Major Pharmaceutical Preparations industry 226 other companies have achieved higher Quick Ratio than Aptevo Therapeutics Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 448 to 1127.

Explain Quick Ratio?
How much Cash & cash equivalents APVO´s has?
What are APVO´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

APVO Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 6.07 % -11.74 % -24.98 % -4.56 % -9.74 %
Y / Y Cash & cash equivalent Change 91.25 % 579.06 % 383.35 % 171.65 % 16.66 %
Quick Ratio MRQ 3.47 3.05 12.77 3.75 1.92
APVO's Total Ranking # 1127 # 448 # 1074 # 1653 # 3400
Seq. Current Liabilities Change 8.99 % 44.33 % -41.25 % 14.78 % -9.31 %
Seq. Cash & cash equivalent Change 23.9 % -65.51 % 99.99 % 123.82 % 339.93 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 227
Healthcare Sector # 378
Overall Market # 1020


Quick Ratio Statistics
High Average Low
12.77 2.83 0.26
(Dec 31 2025)   (Dec 31 2015)




Financial Statements
Aptevo Therapeutics Inc 's Current Liabilities $ 5 Millions Visit APVO's Balance sheet
Aptevo Therapeutics Inc 's Cash & cash equivalent $ 18 Millions Visit APVO's Balance sheet
Source of APVO's Sales Visit APVO's Sales by Geography


Cumulative Aptevo Therapeutics Inc 's Quick Ratio

APVO's Quick Ratio for the trailling 12 Months

APVO Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -8.28 % -11.98 % -12.73 % -18.25 % -20.23 %
Y / Y Cash & cash equivalent TTM Growth 241.6 % 226.62 % 114.84 % -3.84 % -48.43 %
Quick Ratio TTM 5.07 4.69 3.89 2.04 1.36
Total Ranking TTM # 378 # 516 # 650 # 963 # 1030
Seq. Current Liabilities TTM Growth 1.6 % -3.3 % -5.41 % -1.3 % -2.5 %
Seq. Cash & cash equivalent TTM Growth 9.86 % 16.57 % 80.84 % 47.5 % 5.04 %

Quick ratio ranking by company, industry and sector >> Back to APVO Financial Strength Comparisons >> Go to Compare APVO Quick Ratio to its Competitors

On the trailing twelve months basis APVO Cash & cash equivalent soared by 91.25 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Aptevo Therapeutics Inc 's Quick Ratio to 5.07, above APVO average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 423 other companies have achieved higher Quick Ratio than Aptevo Therapeutics Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 3600.

Explain Quick Ratio?
How much Cash & cash equivalents APVO´s has?
What are APVO´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 424
Healthcare Sector # 863
Within the Market # 1127


trailing twelve months Quick Ratio Statistics
High Average Low
4.43 1.91 0.56
(Jun 30 2026)   (Jun 30 2020)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Rezolute Inc   9.44 $ 107.801  Millions$ 11.418  Millions
Crescent Biopharma Inc   9.26 $ 171.593  Millions$ 18.537  Millions
Marker Therapeutics inc   9.10 $ 22.031  Millions$ 2.420  Millions
Synlogic Inc   9.03 $ 13.200  Millions$ 1.461  Millions
Spruce Biosciences Inc   8.78 $ 96.300  Millions$ 10.963  Millions
Newamsterdam Pharma Company N v   8.69 $ 633.854  Millions$ 72.974  Millions
Medicinova Inc   8.58 $ 25.416  Millions$ 2.961  Millions
Lixte Biotechnology Holdings Inc   8.45 $ 12.670  Millions$ 1.500  Millions
Atrium Therapeutics Inc   8.38 $ 264.135  Millions$ 31.508  Millions
Cytomx Therapeutics Inc   8.29 $ 330.280  Millions$ 39.861  Millions
Grace Therapeutics Inc  8.24 $ 13.756  Millions$ 1.669  Millions
Talphera Inc   7.98 $ 33.410  Millions$ 4.188  Millions
Rocket Pharmaceuticals Inc   7.79 $ 342.940  Millions$ 44.031  Millions
Milestone Pharmaceuticals Inc   7.73 $ 171.481  Millions$ 22.184  Millions
Nuvation Bio Inc   7.62 $ 660.956  Millions$ 86.755  Millions
Ibio inc   7.50 $ 88.049  Millions$ 11.745  Millions
Promis Neurosciences inc   7.41 $ 53.463  Millions$ 7.218  Millions
Lakewood-Amedex Biotherapeutics Inc.  7.29 $ 4.585  Millions$ 0.629  Millions
Aspire Biopharma Holdings Inc   7.22 $ 12.167  Millions$ 1.686  Millions
Cartesian Therapeutics Inc   7.18 $ 147.606  Millions$ 20.550  Millions
Kiora Pharmaceuticals Inc   7.10 $ 16.839  Millions$ 2.370  Millions
Arvinas Inc   6.88 $ 567.900  Millions$ 82.500  Millions
Summit Therapeutics Inc   6.67 $ 690.749  Millions$ 103.566  Millions
Alumis inc   6.59 $ 502.300  Millions$ 76.233  Millions
Novelos Therapeutics, Inc.  6.49 $ 33.994  Millions$ 5.238  Millions
Genprex Inc   6.47 $ 15.154  Millions$ 2.342  Millions
Lisata Therapeutics Inc   6.45 $ 19.277  Millions$ 2.987  Millions
Larimar Therapeutics Inc   6.44 $ 219.880  Millions$ 34.166  Millions
United Therapeutics Corporation  6.13 $ 3,724.700  Millions$ 607.800  Millions
Serina Therapeutics Inc   6.12 $ 23.024  Millions$ 3.762  Millions

Date modified: 2026-08-19T04:23:34+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.